Anti-CCR8 antibody is able to selectively eliminate the clonally expanding Treg cells within the tumor, but has no effect on tumor-infiltrating effector T cells or natural Treg cells [180–185], making it a potential treatment for GIST. Here, CCR8 is linked to neoplasm.